Kura Oncology
KURA
104 hedge funds and large institutions have $531M invested in Kura Oncology in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 11 closing their positions.
5,978% more call options, than puts
Call options by funds: $547K | Put options by funds: $9K
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
17% more capital invested
Capital invested by funds: $455M → $531M (+$76.3M)
14% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 28
5% more funds holding
Funds holding: 99 → 104 (+5)
1.26% less ownership
Funds ownership: 85.21% → 83.95% (-1.3%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$13.1M |
| 2 |
Goldman Sachs
New York
|
+$9.57M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.59M |
| 4 |
FI
Fosun International
Hong Kong,
China
|
+$1.57M |
| 5 |
Man Group
London,
United Kingdom
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$16.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.77M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$4.31M |
| 4 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$3.85M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$2.21M |
KURA Hedge Fund Activity: Q1 2019 in Review
104 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q1 2019, worth a combined $531M — up 17% from $455M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new KURA positions and 11 closed out — a net gain of 5 holders — while 32 added to existing stakes and 28 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $13.1M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $16.1M sold.
- 104 institutional investors held Kura Oncology (KURA) as of Q1 2019, up from 99 in Q4 2018.
- Funds reported $531M of Kura Oncology stock for Q1 2019, up 17% quarter-over-quarter.
- 16 funds opened new Kura Oncology positions in Q1 2019 and 11 closed out, a net change of +5 holders.
- The largest Kura Oncology buyer in Q1 2019 was Cormorant Asset Management, an estimated $13.1M added.
- The largest Kura Oncology seller in Q1 2019 was PFM Health Sciences, an estimated $16.1M sold.
Based on aggregated 13F filings for Q1 2019.